Migraine Medication Effects on Urinary Symptoms

Key facts

Sponsor

The Cleveland Clinic

Principal Investigator

Howard B Goldman, MD

The Cleveland Clinic

Intervention

Ubrogepant(drug)

Enrollment

200 target

Eligibility

18 years · FEMALE

Timeline

2024 – 2026

Study locations (1)

• Cleveland Clinic, Main Campus, Cleveland, Ohio, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Interstitial cystitis

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT06752603
  A Clinical Study of ONO-1110 in Patients With Hunner Type Interstitial Cystitis
  Ono Pharmaceutical Co. Ltd
• RECRUITINGEARLY PHASE1NCT04734106
  Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis
  Wake Forest University Health Sciences
• RECRUITINGNANCT06366269
  Acupuncture First for IC/BPS
  University Hospitals Cleveland Medical Center
• RECRUITINGPHASE2NCT06394830
  Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
  Vaneltix Pharma, Inc.
• RECRUITINGNCT06729151
  Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
  Walter Reed National Military Medical Center
• RECRUITINGNCT06719232
  Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation
  Jahn Ferenc South Pest Teaching Hospital
• RECRUITINGPHASE2, PHASE3NCT06096597
  Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome
  David Sheyn
• RECRUITINGNANCT06299683
  Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment
  Vanderbilt University Medical Center

See all trials for Interstitial cystitis →